Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2024 Feb 2;52(3):766–778. doi: 10.1177/03635465231220855

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© 2024 The Author(s)

This article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 License (https://creativecommons.org/licenses/by-nc/4.0/) which permits non-commercial use, reproduction and distribution of the work without further permission provided the original work is attributed as specified on the SAGE and Open Access pages (https://us.sagepub.com/en-us/nam/open-access-at-sage).

PMC Copyright notice

Figure 6. — Systemic TXA treatment reduces tibial osteophyte formation after ACLT. (A) Representative 3-dimensional μCT reconstruction and Bone-Inflammation-Cartilage staining images of osteophytes 4 weeks after ACLT. For the upper panel, osteophytes are shown in red (scale bar = 1 mm); for the lower panel, osteophytes are marked by the black dotted line (scale bar = 100 μm). (B) μCT quantitative analysis of osteophyte volume in the total joint, femoral side, and tibial side. n = 6-7 per group as indicated (1-way ANOVA followed by the Tukey post hoc test). (C) Osteophyte scoring of the total joint, femoral side, and tibial side. n = 5-7 per group as indicated (2-way analysis of variance followed by the Tukey post hoc test). The data are expressed as mean ± SD; *P < .05 for comparisons denoted by bar. μCT, micro−computed tomography; ACLT, anterior cruciate ligament transection; OA, osteoarthritis; TXA, tranexamic acid.